H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on ProQR (PRQR) today and set a price target of $20.00. The company’s shares closed last Friday at $6.23.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 15.3% and a 48.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $23.25, which is a 285.3% upside from current levels. In a report issued on May 7, Evercore ISI also maintained a Buy rating on the stock with a $18.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.46 and a one-year low of $3.40. Currently, ProQR has an average volume of 3.51M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
